AxoGen, Inc. (NASDAQ:AXGN) is set to release its earnings data after the market closes on Tuesday, October 31st. Analysts expect AxoGen to post earnings of ($0.06) per share for the quarter.

AxoGen (NASDAQ:AXGN) last released its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. AxoGen had a negative net margin of 27.50% and a negative return on equity of 114.64%. The company had revenue of $15.20 million for the quarter, compared to analysts’ expectations of $14.40 million. During the same quarter last year, the company earned ($0.09) earnings per share. The firm’s revenue for the quarter was up 46.2% on a year-over-year basis. On average, analysts expect AxoGen to post $-0.33 EPS for the current fiscal year and $-0.09 EPS for the next fiscal year.

Shares of AxoGen, Inc. (AXGN) opened at 20.00 on Tuesday. The firm’s market cap is $664.80 million. AxoGen, Inc. has a 12-month low of $7.65 and a 12-month high of $20.40. The firm’s 50-day moving average is $18.82 and its 200-day moving average is $15.74.

In other AxoGen news, Director Robert James Rudelius sold 16,143 shares of the company’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $18.00, for a total value of $290,574.00. Following the transaction, the director now directly owns 43,273 shares of the company’s stock, valued at approximately $778,914. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 9.33% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “AxoGen, Inc. (AXGN) Set to Announce Earnings on Tuesday” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at

A number of equities analysts have issued reports on the company. Leerink Swann reaffirmed an “outperform” rating and issued a $23.00 target price (up from $22.00) on shares of AxoGen in a research report on Saturday, September 30th. Roth Capital reaffirmed a “buy” rating and issued a $21.00 target price (up from $18.00) on shares of AxoGen in a research report on Tuesday, September 12th. BidaskClub lowered AxoGen from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $18.00 target price on shares of AxoGen in a research report on Monday, August 21st. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $17.40.

AxoGen Company Profile

AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Earnings History for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with's FREE daily email newsletter.